Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

0.6416 -0.0285 (-4.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 782,483
Open 0.6799
Bid (Size) 0.6200 (38)
Ask (Size) 0.6397 (9)
Prev. Close 0.6701
Today's Range 0.6156 - 0.6799
52wk Range 0.4115 - 4.298
Shares Outstanding 38,054,583
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga

Performance

YTD
-77.80%
-77.80%
1 Month
+40.36%
+40.36%
3 Month
-81.29%
-81.29%
6 Month
-74.54%
-74.54%
1 Year
-59.39%
-59.39%

More News

Read More
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
From Athira Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Trade Gap Widens In July
Via Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
Via InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
Via InvestorPlace
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.